[
  {
    "question": "What is the best treatment for hypnic headache?",
    "option_a": "Lithium",
    "option_b": "?",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "Hypnic headache is a rare primary headache that typically affects older adults and is uniquely characterized by occurring exclusively during sleep, often waking the patient up. Its nickname, the 'alarm clock headache', stems from this distinct timing. The exact mechanism remains unclear, but possible dysregulation of the hypothalamic areas controlling circadian rhythms with altered adenosine receptor activity (which caffeine antagonizes) has been implicated in its pathogenesis. The condition is notable for its predictable nocturnal occurrence without the unilateral autonomic features seen in other headaches like cluster headache. Patients often report relief with proper treatment that targets this sleep-related pattern. Diagnosis is made clinically by excluding other nocturnal headaches such as cluster headache, migraine, or sleep apnea. A detailed history regarding the timing and characteristics of the headache is crucial, and the response to treatment (typically caffeine) is informative. The first-line treatment for hypnic headache is caffeine taken about 30 minutes before bedtime, which often provides prompt relief. Lithium is reserved as a second-line option\u2014used in patients who either cannot tolerate caffeine or do not experience adequate relief with it. In the context of pregnancy, high caffeine intake is generally discouraged due to potential fetal risks, so alternative treatments may be considered. During lactation, moderate caffeine use is usually acceptable but should be monitored. Option A (Lithium) is not the best initial treatment due to its side effect profile and need for monitoring, making it a second-line option. Option B (presumed to be Caffeine) is correct as first-line therapy. The other options, although unspecified, do not represent the standard initial approach. 1. Hypnic headache is best managed with a simple intervention\u2014caffeine 30 minutes before sleep. 2. Lithium remains an alternative when caffeine is ineffective or contraindicated. Recent reviews and case series consistently identify caffeine as the first-line treatment for hypnic headache, with lithium being used for refractory cases. This approach is supported by expert consensus in the headache community.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient presented with unilateral headache since few months, sharp, last for less than 1 minute, recurrent daily about 40 times, associated with lacrimation and conjunctival injection, what is the treatment of choice? (2 questions with similar scenario on SUNCT, same answer)",
    "option_a": "Lamotrigine",
    "option_b": "?",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "SUNCT (Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing) is a rare, primary headache disorder defined by very short-lasting, frequent unilateral headache attacks accompanied by cranial autonomic symptoms. Although not completely understood, SUNCT is thought to result from activation of the trigeminal-autonomic reflex and dysfunction within the posterior hypothalamic region. This leads to the rapid onset of pain and accompanying autonomic features like lacrimation and conjunctival injection. Clinically, patients present with brief (lasting seconds to a few minutes) and frequent headache attacks (often dozens per day) that are accompanied by ipsilateral autonomic symptoms, which is a hallmark of the condition. The diagnosis is primarily clinical. Differential diagnoses include cluster headache (which typically lasts longer and occurs in clusters over weeks), paroxysmal hemicrania (which responds to indomethacin), and trigeminal neuralgia. A careful history and neurological examination help distinguish SUNCT from these conditions. Lamotrigine is often considered the first-line prophylactic treatment for SUNCT. For patients with severe or refractory attacks, treatments such as intravenous lidocaine infusions may be employed in an inpatient setting. In pregnant or lactating women, lamotrigine is a relatively safer option among antiepileptics, though serum level monitoring and dose adjustments may be necessary. Option A (Lamotrigine) is accepted as a valid first-line prophylactic for SUNCT. Other possible options, though not specified here, might include topiramate or intravenous lidocaine, but the literature primarily supports lamotrigine for sustained management. 1. SUNCT is characterized by its extremely short, frequent attacks with clear autonomic features. 2. Lamotrigine is the go-to preventive medication for reducing attack frequency in SUNCT. Recent studies and reviews support lamotrigine\u2019s efficacy in managing SUNCT, with evidence showing a reduction in attack frequency and severity. Ongoing research is refining treatment protocols, but current guidelines consistently cite lamotrigine as a mainstay.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "A 40-year-old patient presented with headache for the past 4 months, it is continuous with periods of exacerbation, unilateral side locked, associated with lacrimation, patient is using paracetamol and NSAIDs on a daily basis with no benefits, what is the diagnosis? (two questions with similar scenario on hemicrania continua diagnosis)",
    "option_a": "Hemicrania continua",
    "option_b": "Cluster headache",
    "option_c": "Medication overuse headache",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Hemicrania continua is a unique primary headache disorder characterized by a continuous, strictly unilateral headache with superimposed exacerbations and associated cranial autonomic features. The exact pathogenesis remains partly elusive but involves dysfunction in trigeminal pain pathways and hypothalamic regulatory centers. Its hallmark is the absolute responsiveness to indomethacin, which not only serves as treatment but also as a diagnostic criterion. Patients typically describe a persistent unilateral headache with intermittent periods of severe pain and associated autonomic symptoms such as lacrimation. The continuous nature and lack of response to conventional analgesics point away from diagnoses such as cluster headache or medication overuse headache. Diagnosis is primarily clinical, confirmed by a dramatic response to indomethacin. Differential diagnoses include cluster headache (which is episodic and has distinct timing) and medication overuse headache (which often presents without the unilateral autonomic features seen in hemicrania continua). Indomethacin is the treatment of choice for hemicrania continua, given its near-universal efficacy in relieving symptoms. In pregnant patients, indomethacin is generally avoided (especially in the third trimester due to risks such as premature closure of the ductus arteriosus) and alternative treatments may need to be considered. In lactating women, careful risk-benefit analysis is warranted as indomethacin can be excreted in breast milk. Option A (Hemicrania continua) is the correct diagnosis. Option B (Cluster headache) is inconsistent with the continuous nature of the pain. Option C (Medication overuse headache) does not typically present with strictly unilateral pain and associated lacrimation. 1. Hemicrania continua is uniquely responsive to indomethacin, which is both a diagnostic and therapeutic tool. 2. Its continuous unilateral pain pattern helps differentiate it from other primary headache disorders. Recent clinical guidelines emphasize the role of an indomethacin trial in diagnosing hemicrania continua, supported by multiple case series. Special caution is advised when using indomethacin in populations such as pregnant or lactating women, in line with updated safety recommendations.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "40-year-old patient presented with headache for the past 4 months, it is continuous with periods of exacerbation, unilateral side locked, associated with lacrimation, patient tried paracetamol and NSAIDs with no benefits, what is the treatment?",
    "option_a": "Indomethacin",
    "option_b": "?",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Hemicrania continua is a primary headache disorder characterized by a continuous, strictly unilateral headache with superimposed exacerbations and associated cranial autonomic symptoms, such as lacrimation. A diagnostic hallmark is its dramatic and near-complete response to indomethacin. The exact mechanism is not completely understood, but hypotheses include dysregulation of the trigeminal-autonomic reflex and involvement of central pain pathways. Indomethacin\u2019s efficacy suggests an important role of prostaglandin pathways and inflammatory mediators in this condition. A 40\u2010year\u2010old with a chronic, continuous headache that periodically worsens, is strictly unilateral and accompanied by lacrimation fits the classic clinical picture of hemicrania continua. Failure to respond to common analgesics such as paracetamol and NSAIDs further supports this diagnosis. Diagnosis is made clinically supported by the dramatic response to an indomethacin trial. Differential diagnoses include cluster headache (which has distinct periodic attacks) and paroxysmal hemicrania (which has shorter, more frequent attacks). Neuroimaging is recommended to rule out secondary causes. Indomethacin is the first\u2010line treatment. Typical regimens involve doses ranging from 75 mg to 150 mg per day in divided doses. Caution is required in pregnancy and lactation; indomethacin is contraindicated in the third trimester because it may cause premature closure of the fetal ductus arteriosus, and alternative therapies should be considered in such cases. Option A (Indomethacin) is correct because it is the gold-standard treatment for hemicrania continua. The absence of other viable options in the list further supports this selection. 1. A dramatic response to indomethacin is both therapeutic and diagnostic for hemicrania continua. 2. It is essential to distinguish hemicrania continua from other unilateral headaches such as cluster headache by noting its continuous nature. Recent guidelines and studies continue to affirm indomethacin as the treatment of choice for hemicrania continua, reinforcing its unique efficacy compared to other NSAIDs or analgesics.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "10 years old boy has headache that preceded by red circular colors for few seconds most likely Dx?",
    "option_a": "Occipital seizures",
    "option_b": "Migraine",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "Migraine with aura in children often presents with transient visual symptoms that precede the headache. Common visual auras include scintillating scotomas, zigzag lines, or even simple geometric shapes and colors. Occipital seizures, although they may also produce visual phenomena, typically present with other seizure-related symptoms. In migraine with aura, cortical spreading depression, a wave of neuronal and glial depolarization, is believed to cause the transient visual disturbances. In contrast, occipital seizures result from abrupt, paroxysmal electrical discharges in the occipital cortex. The duration and associated features help differentiate the two. In this 10\u2010year\u2010old boy, the description of visual phenomena as 'red circular colors' followed by headache more typically aligns with migraine with aura. Migrainous visual auras usually last several minutes (though occasionally shorter in children), whereas occipital seizures are usually extremely brief (lasting only a few seconds) and may be accompanied by other signs of seizure activity such as altered awareness or motor phenomena. A detailed history focusing on the duration, evolution, and associated symptoms of the visual phenomenon is key. EEG may be considered if seizure activity is suspected. Differential diagnoses include occipital epilepsy (characterized by very brief, stereotyped visual hallucinations) and other causes of visual disturbances. For pediatric migraine with aura, first-line treatment is supportive care with analgesics such as acetaminophen or ibuprofen, coupled with hydration and rest. In cases where simple analgesics fail, triptans may be considered (usually in children older than 12 years). During pregnancy or lactation, acetaminophen is preferred due to its well\u2010established safety profile. Option A (Occipital seizures) is less likely because the typical seizure-related visual phenomena are extremely brief and often accompanied by additional seizure features. Option B (Migraine) better explains the sequence of visual aura followed by headache and is the most common diagnosis in this age group. Thus, the marked answer A is incorrect. 1. In children, migraine auras, although sometimes brief, typically last longer than a few seconds and are followed by headache. 2. Always consider the full clinical context; isolated visual phenomena in children are more often migrainous than epileptic in origin. Recent studies emphasize the importance of detailed history in differentiating migraine aura from epileptic phenomena in the pediatric population, with migraine being significantly more common than occipital lobe seizures in children presenting with visual disturbances.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "What is the first line Rx for migraine in children?",
    "option_a": "acetaminophen",
    "option_b": "Triptans",
    "option_c": "aspirin",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "In children with migraine, the first-line acute treatment typically involves the use of simple analgesics. Acetaminophen (paracetamol) is widely recommended due to its safety profile, ease of administration, and effectiveness in relieving mild to moderate migraine pain. Migraine involves activation of the trigeminovascular system with the release of neuropeptides that lead to inflammation and vasodilation. Acetaminophen works centrally to reduce pain perception, although its precise mechanism in migraine is not entirely delineated. A child presenting with migraine symptoms often benefits from acetaminophen or NSAIDs. In contrast, other options like triptans are usually reserved for more severe or refractory cases and are not typically the first choice in the pediatric population. Diagnosis of pediatric migraine is clinical. Differential diagnoses include tension-type headaches and secondary headaches. History, physical exam, and exclusion of red flags are essential before initiating treatment. First-line treatment for acute migraine in children includes acetaminophen and NSAIDs. Triptans may be considered as a second-line option in appropriately selected children (usually those older than 12 years). Aspirin is contraindicated due to the risk of Reye syndrome. In pregnancy or lactation, acetaminophen is considered safe and remains the treatment of choice. Option A (Acetaminophen) is correct because it is safe and effective for the initial management of migraine in children. Option B (Triptans) are generally second-line and require careful age and contraindication consideration. Option C (Aspirin) is contraindicated in pediatric patients because of the risk of Reye syndrome. 1. Always use acetaminophen or ibuprofen as first-line therapy for pediatric migraine to avoid the risks associated with aspirin. 2. Triptans are not first-line in young children and should be reserved for cases unresponsive to simpler therapies. Recent pediatric headache guidelines support the use of acetaminophen as an effective first-line therapy for migraine, with multiple studies confirming its safety profile in children compared to alternative treatments.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "50yrs old male with hx of migraine recently dx MI and coronary artery disease what is contraindicated to use regarding preventive treatment of migraine?",
    "option_a": "Amitriptyline",
    "option_b": "Verapamil",
    "option_c": "Triptan??",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "Triptans are a class of serotonin (5-HT1B/1D) receptor agonists used in the acute treatment of migraine. Their mechanism includes vasoconstriction of cranial blood vessels. In patients with established coronary artery disease (CAD) or a history of myocardial infarction (MI), these vasoconstrictive effects can pose significant risks. Triptans cause constriction of both intracranial and coronary vessels. In patients with coronary artery disease or post-MI status, this vasoconstriction can precipitate ischemic events or worsen existing cardiac conditions, making their use contraindicated in these populations. A 50-year-old male with a history of migraine and a recent diagnosis of MI and coronary artery disease is at a high risk for coronary vasospasm and subsequent myocardial ischemia if treated with triptans. Prophylactic or abortive use of triptans in such patients is contraindicated. Before initiating migraine therapy, especially abortive therapies like triptans, a thorough cardiovascular evaluation is essential. Differentiation among migraine treatments is made based on patient-specific comorbidities. In patients with migraine and significant cardiovascular disease, alternatives for acute treatment include options that do not induce vasoconstriction (e.g., acetaminophen, NSAIDs if not contraindicated). For prophylaxis, agents such as amitriptyline or even beta-blockers (which in fact may benefit CAD) can be considered. Pregnancy and lactation add additional layers of consideration; many of these medications require careful assessment, but in cardiac patients, the contraindication of triptans remains absolute. Option A (Amitriptyline) is a tricyclic antidepressant often used for migraine prevention and is not contraindicated in patients with coronary artery disease when used judiciously. Option B (Verapamil) is a calcium channel blocker that, despite its potential cardiac effects, can be used in selected patients for migraine prophylaxis; in fact, it is sometimes preferred in those with contraindications to beta-blockers. Option C (Triptan) is the correct answer as it is contraindicated due to its potent coronary vasoconstrictive effects, particularly in patients with a recent MI and established coronary artery disease. 1. Always screen for cardiovascular comorbidities before prescribing triptans. 2. Triptans are contraindicated in patients with a history of myocardial infarction or significant coronary artery disease regardless of whether they are used for acute or preventive treatment. Current clinical guidelines and safety communications from regulatory agencies continue to list triptans as contraindicated in patients with ischemic heart disease. Updated studies emphasize the need for alternative migraine therapies in this population to avoid serious cardiovascular events.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "Orgasm headache, young lady with severe headache and similar episode every time:",
    "option_a": "Verapamil",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "Primary headache associated with sexual activity (often termed orgasmic headache) is a recognized benign disorder in which severe headache occurs during or immediately after sexual activity, particularly at orgasm. It is considered a primary headache disorder once secondary causes have been ruled out. The exact mechanism is not fully delineated. However, a sudden Valsalva\u2010like increase in blood pressure during sexual activity may lead to transient intracranial vascular changes. Some propose that abnormal cerebrovascular reactivity contributes to these headaches. In patients with structural vascular abnormalities, similar pain can herald a more sinister secondary cause; hence, careful evaluation is important. Patients typically describe a sudden, severe, and often bilateral or holocephalic headache that occurs at the moment of orgasm. The repeated and consistent triggering is a key clinical clue. Importantly, while most cases are primary, clinicians must be vigilant for red flags that might suggest underlying pathology like aneurysms or arteriovenous malformations. The initial approach involves a detailed history and neurologic examination. Neuroimaging \u2013 typically MRI/MRA \u2013 is recommended to exclude secondary causes (e.g., subarachnoid hemorrhage, vascular malformations, dissections). Differential diagnoses include exertional headache, cough headache, and headaches due to intracranial pathology. Once secondary causes are excluded, management is largely symptomatic and preventive. A tiered therapeutic approach is recommended:\n\u2022 First-line: Pre-emptive therapy such as NSAIDs (e.g., indomethacin 25-50 mg taken 30\u201360 minutes before sexual activity) or beta\u2010blockers (e.g., propranolol) may be used prophylactically.\n\u2022 Second-line: If these fail or if contraindications exist, other agents may be considered.\nPregnancy/Lactation Considerations: NSAIDs like indomethacin should be avoided especially in the third trimester due to risks of premature closure of the ductus arteriosus. Beta\u2010blockers require careful monitoring; some (such as labetalol) have a better profile in pregnancy, but propranolol is usually category C. A risk\u2013benefit discussion is mandatory. Option A (Verapamil) is a calcium channel blocker more commonly used in cluster headache prophylaxis rather than orgasmic headache. Option B (the marked answer) is assumed to represent the accepted prophylactic medication (typically an NSAID such as indomethacin or a beta-blocker) for primary orgasmic headache. Options C and D are not provided or are not standard treatments for this condition. \u2022 Always rule out secondary causes by appropriate imaging before labeling a headache as primary orgasmic headache.\n\u2022 Pre-coital prophylaxis (with NSAIDs or beta blockers) taken 30\u201360 minutes before sexual activity can considerably reduce headache occurrence.\n\u2022 A detailed sexual and headache history is key to distinguishing this entity from other primary exertional headaches. Recent reviews and the ICHD-3 criteria emphasize the importance of a careful evaluation to exclude secondary causes. Although large randomized controlled trials are lacking, published case series support the pre-emptive use of indomethacin or beta\u2010blockers. Research continues to explore the underlying neurovascular dynamics and optimal preventive strategies.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "35-year-old women with headache, describes 10 episodes a day of sharp pain over the left eye, which last about 5 minutes and actually cause her for most of the day. Sometimes she tries to sit or lie quietly until the attacks passes. Which of the following autonomic phenomenon is most commonly associated with this type of headache?",
    "option_a": "Lacrimation",
    "option_b": "Conjunctival injection",
    "option_c": "Horner syndrome",
    "option_d": "Photophobia",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "This scenario describes a trigeminal autonomic cephalalgia (TAC), such as cluster headache or related disorders, where severe unilateral periorbital pain is accompanied by autonomic symptoms. TACs involve activation of the trigeminal-autonomic reflex. This leads to parasympathetic outflow causing ipsilateral lacrimation, conjunctival injection, nasal congestion, and sometimes rhinorrhea. Hypothalamic activation is also thought to play a central role in triggering these attacks. Patients usually present with a strictly unilateral headache localized around the orbital region. The accompanying autonomic symptoms \u2014 especially lacrimation \u2014 are almost pathognomonic. The severe pain can result in restlessness, although in some forms (like paroxysmal hemicrania or SUNCT) the pain may be shorter in duration but highly frequent. Differential diagnoses include migraine (which typically has longer duration and often bilateral symptoms with photophobia and phonophobia), cluster headache, paroxysmal hemicrania (which has a dramatic response to indomethacin), and secondary causes (such as ocular pathology). Detailed history, clinical examination, and sometimes neuroimaging help differentiate these conditions. Acute treatment of TACs usually involves high-flow oxygen and subcutaneous sumatriptan for cluster headaches. Prophylactic treatment often includes verapamil as the first-line agent. In pregnant or lactating women, oxygen therapy is safe for acute attacks; caution is required with triptans and verapamil, and treatment must be individualized. Option A (Lacrimation) is the correct answer because lacrimation is the most commonly reported autonomic phenomenon in these headaches. Option B (Conjunctival injection) is also common but slightly less sensitive as an isolated finding. Option C (Horner syndrome) is less frequently seen and not typical. Option D (Photophobia) is more associated with migraine than with TACs. \u2022 In cluster headache and related TACs, lacrimation is almost always present as a key autonomic sign.\n\u2022 The short, recurrent episodes (often several per day) help differentiate TACs from other unilateral headache syndromes.\n\u2022 A focused history on associated autonomic features is crucial to guide diagnosis. The latest literature reinforces the role of lacrimation and other cranial autonomic features in diagnosing TACs. Advanced imaging studies further support hypothalamic involvement in cluster headaches, refining therapeutic approaches and supporting guideline-based acute and preventative management strategies.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "A 25-year-old man presents with episodic, unilateral, throbbing headaches associated with nausea and light and noise sensitivity. They are triggered by some foods including cheddar cheese. Most of his headaches occur without any obvious precipitant. He is having one headache generally occur on the weekend but keep him from his regular activities on the days they occur. He had this occurring at least 1 to 2 days per week of at least 50%-time loss. He has tried multiple over the counter remedies without satisfactory relief. Which of the following medications for symptomatic treatment of his headache would be most appropriate at this time?",
    "option_a": "Aspirin with metoclopramide",
    "option_b": "A triptan",
    "option_c": "Butalbital, caffeine, acetaminophen (APAP) combination",
    "option_d": "Codeine with APAP",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Headache",
    "explanation": "This case is characteristic of migraine headache, a primary headache disorder marked by recurrent episodes of unilateral, throbbing pain accompanied by nausea, and sensory sensitivities like photophobia and phonophobia. Migraines are thought to involve a combination of neurogenic inflammation, trigeminovascular activation, and complex interactions among cortical, subcortical, and brainstem structures. The release of calcitonin gene\u2010related peptide (CGRP) and other neuropeptides leads to vasodilation and subsequent pain. Patients typically describe moderate to severe, unilateral throbbing pain with associated nausea, vomiting, and light/noise sensitivity. The triggers (such as certain foods like cheddar cheese) and the migrainous time course (lasting hours with significant functional impairment) are indicative of migraine rather than other headache types. Differential diagnoses include tension-type headache (usually bilateral and non-throbbing), cluster headache (typically excruciating, shorter, and associated with autonomic symptoms), and medication overuse headache. A detailed history and application of ICHD criteria help in confirming the diagnosis. Acute symptomatic treatment is indicated for migraines that are moderate to severe and disabling:\n\u2022 First-line: Triptans (e.g., sumatriptan) are recommended once over\u2010the\u2010counter remedies (like NSAIDs) have failed, provided there are no contraindications such as significant cardiovascular disease.\n\u2022 Adjunctive use of antiemetics like metoclopramide can also enhance efficacy and address nausea.\nPregnancy/Lactation Considerations: For pregnant or lactating women, NSAIDs (with caution regarding gestational age) or acetaminophen are generally preferred. Sumatriptan is one of the better\u2010studied triptans in pregnancy (though used only when benefits justify potential risks) and is sometimes considered in lactation with careful monitoring. Option A (Aspirin with metoclopramide) may be effective in milder attacks, but given his significant disability and previous OTC failure, it may not be adequate. Option B (A triptan) is the most appropriate symptomatic treatment for moderate to severe migraine attacks, making it the best choice. Option C (Butalbital, caffeine, acetaminophen combination) has a high potential for medication overuse and dependence. Option D (Codeine with APAP) involves opioids, which are not first-line due to risks of rebound headache and dependence. \u2022 Triptans act by constricting intracranial blood vessels and inhibiting CGRP release, making them highly effective for many migraine sufferers.\n\u2022 Migraines often have identifiable dietary or environmental triggers; avoidance strategies can complement pharmacotherapy.\n\u2022 Overuse of acute medications can lead to medication overuse headache; it is important to educate patients on proper use. Recent guidelines continue to support the use of triptans as first-line therapy for moderate to severe acute migraine attacks. Ongoing research into CGRP antagonists is expanding acute treatment options, and current evidence reinforces appropriate patient selection and contraindications for triptans based on cardiovascular risk.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "patient with headache, lancinating pain in the face, what to do next:",
    "option_a": "CT with contrast.",
    "option_b": "Observation",
    "option_c": "MRI with contrast",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "Lancinating facial pain is most classically described in trigeminal neuralgia. This condition is characterized by brief, electric shock-like pains in the distribution of the trigeminal nerve and is typically triggered by light tactile stimulation. In classical trigeminal neuralgia, microvascular compression of the trigeminal nerve root entry zone is the most commonly implicated mechanism. This chronic irritation leads to focal demyelination and hyperexcitability of the nerve fibers. Secondary causes, such as multiple sclerosis plaques or tumors, can produce similar symptoms. Hence, neuroimaging is essential to rule out these conditions. Clinically, patients report recurrent, lancinating, and severe facial pain triggered by activities such as chewing or touching the face. The pain is typically unilateral and confined to one or more divisions of the trigeminal nerve. The diagnostic workup includes a detailed history and neurologic examination. High-resolution MRI with contrast (including specific sequences like FIESTA or CISS) is the imaging modality of choice to assess for neurovascular compression or other secondary causes (e.g., multiple sclerosis, tumors). CT with contrast is less sensitive for soft tissue and nerve evaluations. Once trigeminal neuralgia is confirmed, first-line medical therapy is with carbamazepine. Other anticonvulsants such as oxcarbazepine may be used if carbamazepine is not tolerated. In refractory cases, surgical options (e.g., microvascular decompression) may be considered.\nPregnancy/Lactation Considerations: Many anticonvulsants carry teratogenic risks. Carbamazepine is associated with neural tube defects (and is generally Pregnancy Category D) and should be used with caution in women of childbearing potential; folic acid supplementation is advised. In lactating mothers, alternative management strategies may need to be considered due to potential drug excretion in breast milk. Option A (CT with contrast) is less sensitive for detecting nerve compression and subtle brainstem pathology. Option B (Observation) is not appropriate given the severity and typical necessity for imaging in trigeminal neuralgia. Option C (MRI with contrast) is the appropriate next step to evaluate for vascular loops, demyelination, or other secondary causes. Option D is not provided. \u2022 Trigeminal neuralgia is typically triggered by light touch; even routine activities such as shaving may provoke pain.\n\u2022 MRI with contrast is the gold standard for evaluation to rule out secondary causes.\n\u2022 Early diagnosis is essential to prevent unnecessary delays in appropriate therapy, which may include pharmacologic and surgical options. Recent advances in high-resolution MRI techniques have improved the ability to detect neurovascular compression in trigeminal neuralgia. Updated guidelines reiterate the need for imaging confirmation before initiating long-term treatment, and while medical management remains the first line, there is growing evidence supporting early surgical evaluation in refractory cases.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "case of paroxysmal hemicrania, what is the treatment:",
    "option_a": "Indomethacin",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Paroxysmal hemicrania is a primary headache disorder belonging to the trigeminal autonomic cephalalgias. It is characterized by strictly unilateral, severe headaches that are brief in duration but occur frequently and are associated with ipsilateral autonomic symptoms. A unique feature of this condition is its dramatic and complete response to indomethacin. The underlying mechanism is thought to involve an abnormal activation of the trigeminal-autonomic reflex, with possible hypothalamic involvement. Indomethacin\u2019s efficacy is believed to be due to its inhibition of prostaglandin synthesis and modulation of pain pathways, which distinguishes paroxysmal hemicrania from other similar headache disorders. Patients typically present with short, recurrent severe unilateral headaches accompanied by autonomic features such as lacrimation, nasal congestion, or eyelid edema. The rapid and complete response to indomethacin is not only therapeutic but also diagnostic, distinguishing it from conditions like cluster headache. Diagnosis is primarily clinical using the International Classification of Headache Disorders (ICHD) criteria. A therapeutic trial of indomethacin is often employed to confirm the diagnosis. Differential diagnoses include cluster headache, SUNCT (Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing), and hemicrania continua. Key differentiators are the headache duration, frequency, and the presence or absence of a complete response to indomethacin. Indomethacin is the first-line treatment. Clinicians should start with a dose that is effective in aborting the attacks while monitoring for gastrointestinal and renal side effects; co-administration of gastroprotective agents may be warranted. In pregnant patients, especially in the later trimesters, caution is required because indomethacin can lead to premature closure of the fetal ductus arteriosus. Risk\u2013benefit discussions are essential, and alternative management strategies may be considered if necessary. Option A (Indomethacin) is correct. Its unique and dramatic response in paroxysmal hemicrania makes it both a diagnostic and therapeutic mainstay. The absence of other options further underscores that indomethacin is the treatment of choice for this condition. 1) A complete and rapid response to indomethacin is almost pathognomonic for paroxysmal hemicrania. 2) Differentiation from cluster headache is based on shorter attack duration, higher frequency, and indomethacin responsiveness. Current clinical guidelines and recent research continue to endorse indomethacin as the gold standard for treating paroxysmal hemicrania, with ongoing emphasis on monitoring for side effects and careful use in special populations, including pregnant women.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "patient with chronic migraine, what is the treatment:",
    "option_a": "propranolol.",
    "option_b": "Depakene",
    "option_c": "Botox",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Headache",
    "explanation": "Chronic migraine is defined as headache occurring on 15 or more days per month for more than 3 months (with at least 8 migraine days). OnabotulinumtoxinA (Botox) is an FDA-approved prophylactic treatment for chronic migraine and has been validated in several large-scale clinical trials. Chronic migraine is believed to be driven by central sensitization and dysregulation of pain modulatory systems. Botulinum toxin is thought to reduce migraine frequency by inhibiting the release of pain-mediating neuropeptides such as CGRP and modulating peripheral and central pain pathways. Patients with chronic migraine experience frequent and debilitating headaches that significantly impair daily functioning. OnabotulinumtoxinA has been shown to reduce both the number of headache days and headache severity, improving quality of life. Diagnosis is clinical, based on ICHD criteria. It is essential to distinguish chronic migraine from medication overuse headache, tension-type headache, and other secondary headache disorders. A detailed headache diary is often used for this purpose. First-line treatment for chronic migraine prophylaxis includes onabotulinumtoxinA injections administered every 12 weeks following the PREEMPT protocol. Second-line options include oral agents such as topiramate, beta-blockers, and tricyclic antidepressants. In pregnant patients, caution is advised with Botox due to limited data; ideally, treatment plans should be re-evaluated, and safer alternatives considered if possible, while acknowledging the risk of uncontrolled headaches. During lactation, a risk\u2013benefit assessment is also crucial. Option C (Botox) is correct. While propranolol (Option A) is effective for episodic migraine, it has less evidence for chronic migraine. Depakene (valproate, Option B) is generally contraindicated in women of childbearing potential and poses significant teratogenic risks. 1) OnabotulinumtoxinA is specifically approved for chronic migraine prophylaxis and can markedly reduce headache frequency. 2) Always consider the possibility of medication overuse when evaluating chronic migraine. Recent large-scale studies, including the PREEMPT trials, have reinforced the efficacy and safety profile of onabotulinumtoxinA in chronic migraine prophylaxis. Updated guidelines continue to recommend Botox as a primary treatment option for chronic migraine with careful evaluation in women of childbearing age.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "patient with migraine, worse with her period:",
    "option_a": "start triptan before her period by 2 days for 7 days.",
    "option_b": "propranolol",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Menstrual migraine is a recognized subtype of migraine that is closely linked to hormonal fluctuations, particularly the drop in estrogen levels during the menstrual cycle. Short-term prophylactic treatment aimed at the perimenstrual period is a well-established management strategy. The precipitous decline in estrogen just prior to menstruation is thought to trigger migraine attacks by modulating serotonin pathways and lowering the pain threshold in susceptible individuals. Triptans, which are serotonin receptor agonists, can thus be used effectively to avert or reduce the severity of these attacks when administered prophylactically. Patients with menstrual migraine typically experience predictable, cyclic headaches that occur in relation to their menstrual period. Given the predictability, clinicians can time short-term prophylaxis to cover the vulnerable period, thereby reducing migraine incidence and severity. Diagnosis is based on a thorough headache and menstrual history. Differential diagnoses include tension-type headache and other hormonally influenced headache syndromes. The pattern of headache occurrence that consistently correlates with the menstrual cycle strongly supports the diagnosis. The first-line management for menstrual migraine includes short-term prophylaxis with a triptan. The recommended regimen is to initiate a triptan 1\u20132 days before the expected onset of menses and continue for approximately 5\u20137 days. NSAIDs are also sometimes used, but triptans have robust evidence supporting their efficacy in this setting. For pregnant patients, caution is warranted, and non-pharmacologic strategies are generally preferred if possible, while lactating mothers should engage in a careful risk\u2013benefit discussion. Option A (start triptan before her period by 2 days for 7 days) is the correct choice as it aligns with current evidence for short-term prophylaxis in menstrual migraine. Propranolol (Option B) is typically used for long-term, continuous migraine prophylaxis rather than for the targeted short-term prophylaxis required for menstrual migraine. 1) The predictable nature of menstrual migraines allows for effective short-term prophylaxis. 2) Initiating treatment before the onset of symptoms can significantly reduce the severity and duration of the migraine attack. Recent clinical guidelines and systematic reviews continue to advocate for short-term triptan prophylaxis in menstrual migraine, with studies confirming its efficacy when timed appropriately relative to the menstrual cycle.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "patient with migraine on amitriptyline & sumatriptan, became pregnant what to do?",
    "option_a": "keep the same & encourage taking multivitamin",
    "option_b": "discontinue sumatriptan",
    "option_c": "discontinue amitriptyline",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Managing migraine during pregnancy requires a careful balance between controlling maternal symptoms and minimizing fetal exposure to potentially harmful medications. Both amitriptyline (a prophylactic agent) and sumatriptan (an abortive agent) have been studied in pregnancy and are generally considered acceptable when the benefits outweigh potential risks. Amitriptyline acts by modulating central neurotransmitter levels, reducing the frequency of migraine attacks, while sumatriptan, a selective serotonin receptor agonist, aborts acute migraine episodes. Data from pregnancy registries have not shown significant teratogenic effects for either medication when used appropriately in early pregnancy. Uncontrolled migraines in pregnancy can lead to significant maternal distress, disability, and even potential complications due to stress and frequent pain. Maintaining effective migraine control is therefore important for overall maternal health and quality of life. A detailed review of the patient's headache history, medication use, and risk factors is essential. The benefit of controlling severe headaches must be weighed against any theoretical risks from medication exposure during pregnancy. Current guidelines suggest that if a woman with migraine becomes pregnant and her current regimen (amitriptyline plus sumatriptan) is effective, it is generally advisable to continue the therapy to prevent breakthrough headaches and maintain quality of life. In addition, folic acid supplementation (as part of a multivitamin) is recommended in pregnancy to reduce the risk of neural tube defects. During lactation, both medications are used with caution but generally result in low infant exposure. Option A (keep the same & encourage taking multivitamin) is correct because it supports the continuation of effective migraine management while adding multivitamin use (notably folic acid) to benefit fetal development. Option B (discontinue sumatriptan) is incorrect, as sumatriptan has robust safety data in pregnancy and discontinuing it might lead to uncontrolled migraines. Option C (discontinue amitriptyline) is similarly unjustified, as both medications contribute to overall migraine control without significant teratogenic risk when used appropriately. 1) Sumatriptan is the most extensively studied triptan in pregnancy and is generally considered safe when used for acute migraine episodes. 2) Continuation of effective prophylactic therapy, including amitriptyline, can prevent the morbidity associated with poorly controlled migraines in pregnancy. Recent research, including data from pregnancy registries and meta-analyses, supports the continued use of sumatriptan and amitriptyline during pregnancy when indicated. The consensus is that the maternal benefits of controlling migraines typically outweigh the potential risks, reinforcing the importance of individualized risk\u2013benefit assessments.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "patient with cluster headache, treatment:",
    "option_a": "Verapamil",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Cluster headache is a primary headache disorder that falls under the trigeminal autonomic cephalalgias. It is distinguished by its strictly unilateral orbital, temporal or supraorbital pain accompanied by ipsilateral autonomic symptoms such as lacrimation, nasal congestion, and sometimes ptosis. Attacks often occur in clusters over weeks or months with a circadian rhythmicity. The underlying mechanism involves activation of the hypothalamus, which is thought to drive the trigeminal-autonomic reflex. This results in the release of vasoactive neuropeptides and inflammatory mediators. Evidence suggests that hypothalamic dysfunction triggers parasympathetic outflow, contributing to the characteristic autonomic symptoms. Patients experience extremely severe, unilateral, and short-lived headache attacks that can occur multiple times a day. The presence of autonomic symptoms like lacrimation and nasal congestion during attacks helps differentiate cluster headache from other headache disorders. The cyclical pattern of attacks further supports the diagnosis. Diagnosis is made clinically according to criteria set by the International Classification of Headache Disorders. Differential diagnoses include migraine (which has a longer duration and is commonly pulsatile), paroxysmal hemicrania (which is usually more frequent and highly responsive to indomethacin), and SUNCT syndrome. Neuroimaging is generally reserved to exclude secondary causes. Acute treatment includes high\u2010flow oxygen (12 L/min via non\u2010rebreather mask) and subcutaneous sumatriptan. For prophylaxis during a cluster period, verapamil is the first\u2010line treatment. In pregnancy and lactation, oxygen is safe for acute attacks while caution is advised with triptans and verapamil due to limited safety data, so therapy should be individualized balancing risks and benefits. Regular ECG monitoring is recommended with verapamil due to possible cardiac conduction issues. Option A: Verapamil is the correct answer when considering prophylactic treatment for cluster headache. Although acute management involves oxygen or triptans, verapamil is the standard for preventing or reducing the frequency of cluster headache attacks, which aligns with the question\u2019s context. 1. Cluster headaches typically follow a circadian pattern and may occur in clusters over weeks. 2. Prophylactic therapy with verapamil requires gradual dose escalation with ECG monitoring. 3. High\u2010flow oxygen remains the mainstay of acute treatment. Recent clinical studies and guidelines continue to endorse verapamil as the first-line prophylactic agent for cluster headaches. Ongoing research into the role of CGRP and other neuropeptides may offer future therapeutic targets.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "Young female presented with with severe headache; CT showing",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "1",
    "subspecialty": "Headache",
    "explanation": "Pituitary apoplexy is an endocrinological and neurological emergency marked by a sudden hemorrhage or infarction of the pituitary gland, most commonly in a preexisting pituitary adenoma. It presents acutely with severe headache and signs of pituitary insufficiency. The apoplectic event is caused by hemorrhagic or ischemic injury within the pituitary, leading to rapid expansion and compression of adjacent structures (such as the optic chiasm) and pituitary tissue. Factors like large adenoma size, hypertension, and anticoagulation use may precipitate the event. Patients often present with a sudden, severe headache often described as the worst headache of their life, accompanied by visual disturbances (like bitemporal hemianopia), ophthalmoplegia, nausea, and altered mental status. In young females, pituitary apoplexy may be the first presentation of a previously undiagnosed adenoma. Diagnosis relies on clinical suspicion supported by neuroimaging. CT can reveal hemorrhage in the sellar region, although MRI is more sensitive. Differential diagnoses include subarachnoid hemorrhage (which typically shows blood in the subarachnoid spaces), meningitis (associated with fever and neck stiffness), and intracerebral hemorrhage (with different imaging features). Immediate management involves high-dose corticosteroids to manage potential adrenal insufficiency and reduce inflammation. Fluid and electrolyte support is essential. Depending on the severity of visual or neurological deficits, transsphenoidal decompression surgery may be required. In pregnant patients, steroids remain critical, and timing of surgery is optimized to reduce risk to the fetus while managing the mother\u2019s condition. Option 1 (Pituitary apoplexy) is correct because the clinical scenario (young female with acute severe headache and CT evidence of sellar hemorrhage) is most consistent with this diagnosis. Other differentials like subarachnoid hemorrhage or migraine are less likely given the localized imaging findings and the endocrine emergency nature of the condition. 1. Pituitary apoplexy is an endocrine emergency \u2013 early recognition and treatment can prevent permanent deficits. 2. Look for signs of pituitary hormone deficiency and visual disturbances in the context of an acute sellar hemorrhage. 3. MRI is more sensitive than CT for detecting pituitary hemorrhage, but CT can provide rapid information in the emergency setting. Recent guidelines stress early intervention with corticosteroids and careful evaluation of the need for surgical decompression. Emerging studies are focusing on improved imaging techniques and timing of surgical management to optimize outcomes.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Male pt came with shock like electric sensation in half of face multiple times per day avoiding brushing and shaving Rx?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "1",
    "subspecialty": "Headache",
    "explanation": "Trigeminal neuralgia is characterized by brief, episodic, shock-like facial pain typically affecting one side of the face. It most commonly involves the distribution of the trigeminal nerve and is frequently triggered by light touch, such as during brushing or shaving. The condition is most often due to neurovascular compression at the root entry zone of the trigeminal nerve, leading to focal demyelination. This demyelination results in hyperexcitability of the nerve fibers, allowing otherwise normal stimuli to trigger ectopic impulse generation. Voltage-gated sodium channel dysfunction also plays a significant role. Patients present with severe, paroxysmal, unilateral facial pain described as electric shocks. These brief episodes are often triggered by innocuous stimuli such as touching the face, brushing teeth, or shaving. The recurrent, stereotyped nature of the attacks and the trigger zones are diagnostic hallmarks. The diagnosis is primarily clinical based on the characteristic history. Differential diagnoses include dental pain, atypical facial pain, postherpetic neuralgia, and less commonly, migraine. MRI is used to rule out secondary causes like multiple sclerosis plaques or tumors compressing the trigeminal nerve. Carbamazepine is the first-line treatment for trigeminal neuralgia due to its efficacy in reducing paroxysmal pain by blocking sodium channels. Alternatives include oxcarbazepine. For refractory cases, second-line medications like gabapentin or lamotrigine can be tried, and surgical interventions (e.g., microvascular decompression) are reserved for those who do not respond to medical therapy. In pregnant patients, carbamazepine is used with caution due to its teratogenic potential and is often supplemented with folate; careful risk-benefit analysis is crucial. Option 1 (Carbamazepine) is correct because it directly targets the pathophysiology of trigeminal neuralgia by stabilizing hyperexcitable neuronal membranes. Other options such as NSAIDs, opioids, or antidepressant medications are not effective first-line treatments for the paroxysmal neuropathic pain seen in trigeminal neuralgia. 1. The hallmark of trigeminal neuralgia is shock-like pain triggered by routine facial activities. 2. Carbamazepine is the gold standard treatment, but monitoring for side effects like hyponatremia and liver enzyme disturbances is necessary. 3. Differentiate TN from dental pain early to avoid unnecessary dental procedures. Contemporary studies and guidelines consistently support the use of carbamazepine as first-line therapy for trigeminal neuralgia. Newer research is focused on understanding genetic predispositions and exploring alternative sodium channel blockers to improve patient outcomes.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Male pt came with shock like electric sensation in half of face multiple times per day avoiding brushing and shaving dx?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "1",
    "subspecialty": "Headache",
    "explanation": "Trigeminal neuralgia is a disorder characterized by sudden, severe, electric shock-like facial pain that is typically unilateral and occurs in brief paroxysms. Its distinctive feature is the triggering of pain by light sensory stimuli in designated trigger zones (e.g., while brushing or shaving). Often caused by vascular compression at the trigeminal nerve\u2019s root entry zone, the resulting demyelination predisposes the nerve to inappropriate electrical firing. This abnormal conduction through demyelinated fibers accounts for the sudden, sharp pain episodes seen in trigeminal neuralgia. Patients usually report brief, excruciating bouts of facial pain that may last several seconds and are triggered by ordinary stimuli, such as brushing the teeth or applying makeup. The unilateral nature of the pain and the existence of trigger zones are key features that help distinguish it from other forms of facial pain. Diagnosis is mainly clinical, based on the history of paroxysmal, triggerable facial pain. Differential diagnoses include postherpetic neuralgia (which typically follows a shingles outbreak and presents with a burning pain), dental pain, temporomandibular joint disorders, and cluster headache. MRI is often utilized to rule out secondary causes like demyelinating lesions or tumors. The mainstay of treatment is pharmacological management with agents such as carbamazepine or oxcarbazepine. For cases that are refractory to medication, surgical options such as microvascular decompression are considered. In pregnant patients, the use of carbamazepine requires cautious risk-benefit evaluation along with folate supplementation due to potential teratogenic effects, with alternatives considered if available. Option 1, which confirms the diagnosis of trigeminal neuralgia, is appropriate given the description of shock-like facial pain triggered by routine activities. Other conditions in the differential do not exhibit the same paroxysmal, triggerable profile or are accompanied by other distinct features absent in this scenario. 1. A positive trigger zone is a classic diagnostic clue for trigeminal neuralgia. 2. Early, accurate diagnosis is essential to prevent unnecessary procedures and provide effective pain relief. 3. Individualizing treatment is key, especially in special populations such as pregnant women. Latest guidelines and clinical research continually reaffirm the role of carbamazepine as first-line management for trigeminal neuralgia. Ongoing trials are investigating alternative agents and novel surgical techniques to improve long-term outcomes with fewer adverse effects.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  },
  {
    "question": "Patient with headache and recurrent thunderclap headache with normal MRI and MRV:",
    "option_a": "correctly points to RCVS, given the presentation of recurrent thunderclap headaches with normal initial MRI and MRV. Other options likely represented diagnoses such as subarachnoid hemorrhage, cerebral venous sinus thrombosis, or cervical artery dissection, which would typically show abnormalities on imaging or have different clinical courses.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Headache",
    "explanation": "Reversible Cerebral Vasoconstriction Syndrome (RCVS) is characterized by sudden, severe 'thunderclap' headaches that may recur over days to weeks. Despite the dramatic clinical presentation, early structural imaging (MRI/MRV) can be normal. The key diagnostic clue is the presence of segmental vasoconstriction on vascular imaging that reverses over time. RCVS is thought to result from dysregulation of cerebral arterial tone leading to multifocal, reversible vasoconstriction. It is associated with various triggers such as vasoactive substances, postpartum state, or exposure to certain medications. The transient nature of the vasospasm explains why initial MRI/MRV studies may not reveal acute changes. Patients typically present with recurrent thunderclap headaches, sometimes described as the worst headache of their life. While early neuroimaging is often unremarkable, additional studies later in the course may reveal the characteristic arterial narrowing. This condition is usually self-limited and resolves over a period of weeks to months. The work-up includes non-contrast CT to rule out subarachnoid hemorrhage, followed by lumbar puncture if CT is negative. Vascular imaging (CTA, MRA, or conventional angiography) is indicated to detect the segmental vasoconstriction. Differential diagnoses include subarachnoid hemorrhage (which would show blood or xanthochromia on LP), cerebral venous sinus thrombosis (abnormal MRV findings), cervical artery dissection (focal vessel wall abnormalities on MRA/MRI), and primary thunderclap headache (a diagnosis of exclusion). The mainstay of treatment is supportive care with analgesics for headache relief. Calcium channel blockers (e.g., nimodipine) are often used to alleviate vasospasm. Blood pressure control and avoidance of triggers are important. In pregnancy and lactation, treatment should be carefully balanced; for instance, if a pregnant patient develops RCVS, medications with a known safety profile in pregnancy (such as labetalol for blood pressure management) should be considered, and consultation with maternal-fetal medicine is advised. Option A correctly points to RCVS, given the presentation of recurrent thunderclap headaches with normal initial MRI and MRV. Other options likely represented diagnoses such as subarachnoid hemorrhage, cerebral venous sinus thrombosis, or cervical artery dissection, which would typically show abnormalities on imaging or have different clinical courses. 1. RCVS often presents with recurrent, sudden-onset headaches despite normal initial imaging studies. 2. Definitive diagnosis may require vascular imaging showing reversible arterial narrowing. 3. Management is largely supportive with consideration of calcium channel blockers. Recent literature supports that RCVS is self-limiting and that calcium channel blockers may reduce headache intensity. However, there remains a lack of large prospective studies to firmly establish treatment guidelines, emphasizing the importance of ruling out mimics such as subarachnoid hemorrhage.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  }
]